Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites

Journal of Clinical Investigation

Volumn 100, Issue 3, 1997, Pages 664-670

  López Talavera, Juan Carlos ^a   Levitzki, Alexander ^b   Martínez, Moisés ^a   Gazit, Aviv ^b   Esteban, Rafael ^a   Guardia, Jaime ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Liver cirrhosis; Protein tyrosine kinase; Signal transduction; Tumor necrosis factor vasodilation

Indexed keywords

5 (2,2 DICYANOVINYL) 2 NITROPHENOL; ALPHA CYANO (3 HYDROXY 4 NITRO)CINNAMONITRILE; ALPHA CYANO 4 HYDROXYCINNAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CONTROLLED STUDY; DOSE RESPONSE; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SYSTEMIC VASCULAR RESISTANCE;

EID: 1842295670     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119578     Document Type: Article

References (44)

1. Genecin, P., and R.J. Groszmann. 1993. Portal hypertension. In Diseases of the Liver. 7th ed. E. Schiff and L. Schiff, editors. J.B. Lippincott Co., Philadelphia, PA. 2:935-973.
2. Pizcueta, P., J.M. Pique, M. Fernandez, J. Bosch, J. Rodes, B.J.R. Whittle, and S. Moncada. 1992. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology. 103:1909-1915.
3. Whittle, B.J.R., and S. Moncada. 1992. Nitric oxide: the elusive mediator of the hyperdynamic circulation of cirrhosis? Hepatology. 16:1089-1092.
4. Lee, F.Y., A. Albillos, L.A. Colombato, and R.J. Groszmann. 1992. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology. 16:1043-1048.
5. Pizcueta, M.P., J.M. Pique, J. Bosch, B.J.R. Whittle, and S. Moncada. 1992. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br. J. Pharmacol. 105:184-190.
6. Old, L.J. 1985. Tumor necrosis factor (TNF-α). Science (Wash. DC). 230: 630-632.
7. Stephens, K.E., A. Ishizaka, J.W. Larryk, and T.A. Raffin. 1988. Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury. Am. Rev. Respir. Dis. 137:1364-1370.
8. Gamble, J.R., J.M. Harlan, S.J. Klebanoff, and M.A. Vadas. 1985. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc. Natl. Acad. Sci. USA. 82:8667-8671.
9. Frater Schroeder, M., W. Risau, R. Hallmann, P. Gautschi, and P. Bohlen. 1987. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Natl. Acad. Sci. USA. 84:5277-5281.
10. Johnson, J., K.L. Brigham, G. Jesmok, and B. Meyrick. 1991. Morphologic changes in lungs of anesthetized sheep following intravenous infusion of recombinant tumor necrosis factor alpha. Am. Rev. Respir. Dis. 144:179-186.
11. Kelly, J. 1990. Cytokines of the lung. Am. Rev. Respir. Dis. 141:765-788.
12. Gross, S.S., E.A. Jaffe, R. Levi, and R.G. Kilbourn. 1991. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochem. Biophys. Res. Commun. 178:823-829.
13. Kilbourn, R.G., and P. Belloni. 1990. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin. J. Natl. Cancer Inst. (Bethesda). 82: 772-776.
14. Westenfelder, C., R. Taintor, Z. Vavrin, C. Kablitz, R.L. Baranowski, J.H. Ward, R.L. Menlove, M.P. McMurry, J.P. Kushner, and W.E. Samlowski. 1992. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J. Clin. Invest. 89:867-877.
15. G-Methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc. Natl. Acad. Sci. USA. 87:3629-3632.
16. Yoshioka, K., S. Kakumu, M. Arao, Y. Tsutsumi, and M. Inque. 1989. Tumor necrosis factor-alpha production by peripheral blood mononuclear cells of patients with chronic liver disease. Hepatology. 10:769-773.
17. Khoruts, A., L. Stahnke, C. McClain, G. Logan, and J.I. Allen. 1991. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology. 13:267-276.
18. Lopez-Talavera, J.C., W. Merrill, and R.J. Groszmann. 1995. Tumor necrosis factor-alpha: a major contributor to the hyperdynamic circulation in prehepatic portal hypertensive rats. Gastroenterology. 108:761-767.
19. Lopez-Talavera, J.C., G. Cadelina, J. Olchowski, W. Merrill, and R.J. Groszmann. 1996. Thalidomide inhibits tumor necrosis factor-alpha, decreases nitric oxide synthesis and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 23:1616-1621.
20. Weinstein, S.L., M.R. Gold, and A.L. De Franco. 1991. Bacterial lipopolysaccharide stimulates protein tyrosine phosphorylation in macrophages. Proc. Natl. Acad. Sci. USA. 88:4148-4152.
21. Victor, I., P. Schwenger, W. Li, J. Schlessinger, and J. Vilcek. 1993. Tumor necrosis factor-induced activation and increased tyrosine phosphorylation of mitogen-activated protein (MAP) kinase in human fibroblasts. J. Biol. Chem. 268:18994-18999.
22. Kilbourn, R.G., and O.W. Griffith. 1992. Overproduction of nitric oxide in cytokine-mediated and septic shock. J. Natl. Cancer Inst. (Bethesda). 84:827-831.
23. Novogrodsky, A., A. Vanichkin, M. Patya, A. Gazit, N. Osherov, and A. Levitzki. 1994. Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science (Wash. DC). 264:1319-1322.
24. Lopez-Novoa, J.M. 1988. Pathophysiological features of the carbon tetrachloride/phenobarbital model of experimental liver cirrhosis in rats. In The Kidney in Liver Disease, 3rd ed. M. Epstein, editor. Elsevier Science Publishing Co. Inc., New York. 309-327.
25. Sieber, C.C., J.C. Lopez-Talavera, and R.J. Groszmann. 1993. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology. 104:1750-1754.
26. Yoneda, T., R.M. Lyall, and M.M. Alsina. 1991. The anti-proliferative effects of tyrosine kinase inhibitors on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 51:4430-4435.
27. Meydan, N., T. Grunberger and H. Dadi. 1996. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (Lond.). 379:645-648.
28. Colombato, L.A., A. Albillos, and R.J. Groszmann. 1991. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology. 15:323-328.
29. Blei, A.T., D.J. O'Reilly, and J. Gottstein. 1984. Portal-systemic shunting and the hemodynamic effects of nitroglycerin in the rat. Gastroenterology. 86:1428-1436.
30. Edelman, G.M., and J.A. Gally. 1992. Nitric oxide: linking space and time in the brain. Proc. Natl. Acad. Sci. USA. 89:11651-11652.
31. Stamler, J.S., D.J. Singel, and J. Loscalzo. 1992. Biochemistry of nitric oxide and its redox-activated forms. Science (Wash. DC). 258:1898-1902.
32. Tilg, H., A. Wilmer, W. Vogel, M. Herold, B. Nolchen, G. Judmaier, and C. Huber. 1992. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 103:264-274.
33. Andus, T., J. Bauer, and W. Gerok. 1991. Effects of cytokines on the liver. Hepatology. 13:364-375.
34. Billiard, T.R., R.D. Curran, B.G. Harbrecht, J. Stadler, D.L. Williams, J.B. Ochoa, M. Di Silvio, R.L. Simmons, and S.A. Murray. 1992. Association between synthesis and release of cGMP and nitric oxide biosynthesis by hepatocytes. Am. J. Physiol. 262:C1077-C1082.
35. Mehta, R., J. Gottstein, W. Patrick Zeller, R. Lichtenberg, and A.T. Blei. 1990. Endotoxin and the hyperdynamic circulation of portal vein-ligated rats. Hepatology. 12:1152-1156.
36. Tartaglia, L.A., M. Rothe, Y.-F. Hu, and D.V. Goeddel. 1993. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF-α receptor. Cell. 73:213-216.
37. Deviere, J., J. Content, C. Denys, P. Vandenbussche, L. Schandene, J. Wybran, and E. Dupont. 1990. Excessive in vitro bacterial lipopolysaccharide-induced production on monokines in cirrhosis. Hepatology. 11:628-634.
38. Sorell, W.T., E.M.M. Quigley, G. Jin, T.J. Johnson, and L.F. Rikkers. 1993. Bacterial translocation in the portal-hypertensive rat: studies in basal conditions and on exposure to hemorrhagic shock. Gastroenterology. 104:1722-1726.
39. Garcia-Tsao, G., A. Albillos, G.E. Barden, and A.B. West. 1993. Bacterial translocation in acute and chronic portal hypertension. Hepatology. 17: 1081-1085.
40. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. 1992. Crit. Care Med. 20:864-874.
41. Parrillo, J.E. 1993. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 328:1471-1477.
42. Glaser, K.B., A. Sung, J. Bauer, and B.M. Weichman. 1993. Regulation of eicosanoid biosynthesis in the macrophage. Involvement of protein tyrosine phosphorylation and modulation by selective protein tyrosine kinase inhibitors. Biochem. Pharmacol. 1993:711-721.
43. Levitzki, A. 1992. Tyrphostins: tyrosine kinase blockers as novel anti-proliferative agents and dissectors of signal transduction. FASEB (Fed. Am. Sco. Exp. Biol.) J. 6:3275-3282.
44. Dong, Z., X. Qi, K. Xie, and I.J. Fidler. 1993. Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in lipopolysaccharide-responsive and lipopolysaccharide-nonresponsive murine macrophages. J. Immunol. 151:2717-2724.